BridgeBio Oncology Therapeutics
Industry
- Pharmaceuticals
- Biotechnology
Other Names/Subsidiaries
- TheRas
See more in Biomedtracker
Latest on BridgeBio Oncology Therapeutics
Scrip
• By Amanda Micklus
One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up
In Vivo
• By Amanda Micklus
A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of
Scrip
• By Mandy Jackson
BridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it